Orexo is a fully integrated specialty pharmaceutical company
Opioid addiction is a treatable chronic disease
Developed 4 products approved worldwide
Embracing all aspects of opioid addiction
We will be recognized for the added value our products bring to patients and societies
Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.
Follow Orexo in social media
When you sign up to our newsletter or press releases, we use the data necessary for this purpose, or the data separately provided by you, to send you our email regularly. You can unsubscribe from our newsletter or press releases at any time via a link provided in the email.